within Pharmacolibrary.Drugs.ATC.N;

model N06AX21
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.0016833333333333333,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 1.62,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0038833333333333337,
    Tlag           = 10.020000000000001,            
    Vdp             = 0.955,
    k12             = 62.3,
    k21             = 62.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06AX21</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) used primarily in the treatment of major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain. It is approved and widely used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after oral administration of duloxetine.</p><h4>References</h4><ol><li><p>Knadler, MP, et al., &amp; Bergstrom, R (2011). Duloxetine: clinical pharmacokinetics and drug interactions. <i>Clinical pharmacokinetics</i> 50(5) 281–294. DOI:<a href=&quot;https://doi.org/10.2165/11539240-000000000-00000&quot;>10.2165/11539240-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21366359/&quot;>https://pubmed.ncbi.nlm.nih.gov/21366359</a></p></li><li><p>Richard, MJ, et al., &amp; McAlindon, TE (2023). Pharmaceutical treatment of osteoarthritis. <i>Osteoarthritis and cartilage</i> 31(4) 458–466. DOI:<a href=&quot;https://doi.org/10.1016/j.joca.2022.11.005&quot;>10.1016/j.joca.2022.11.005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36414224/&quot;>https://pubmed.ncbi.nlm.nih.gov/36414224</a></p></li><li><p>Hanif, N, et al., &amp; Rasool, MF (2023). Clinical pharmacokinetics of nebivolol: a systematic review. <i>Drug metabolism reviews</i> 55(4) 428–440. DOI:<a href=&quot;https://doi.org/10.1080/03602532.2023.2271195&quot;>10.1080/03602532.2023.2271195</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37849071/&quot;>https://pubmed.ncbi.nlm.nih.gov/37849071</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06AX21;
